multiple myeloma	is a	plasma‑cell cancer
multiple myeloma	originates in	bone marrow
multiple myeloma	causes	hypercalcemia
multiple myeloma	leads to	bone pain
multiple myeloma	results in	anemia
multiple myeloma	increases	infection risk
multiple myeloma	is diagnosed with	serum protein electrophoresis
multiple myeloma	is confirmed by	bone marrow biopsy
multiple myeloma	is staged by	International Staging System
multiple myeloma	is treated with	bortezomib
multiple myeloma	is treated with	lenalidomide
multiple myeloma	is treated with	dexamethasone
multiple myeloma	is treated with	autologous stem cell transplant
multiple myeloma	is treated with	carfilzomib
multiple myeloma	is treated with	daratumumab
multiple myeloma	is treated with	pomalidomide
multiple myeloma	is treated with	melphalan
multiple myeloma	is treated with	cyclophosphamide
multiple myeloma	is treated with	thalidomide
multiple myeloma	is treated with	bisphosphonate
multiple myeloma	is treated with	zoledronic acid
multiple myeloma	is treated with	denosumab
multiple myeloma	is monitored by	serum free light chain assay
multiple myeloma	is monitored by	urine Bence‑Jones protein
multiple myeloma	is monitored by	imaging
multiple myeloma	is monitored by	PET‑CT
multiple myeloma	is monitored by	MRI
multiple myeloma	is monitored by	skeletal survey
multiple myeloma	is associated with	renal failure
multiple myeloma	is associated with	hyperviscosity syndrome
multiple myeloma	is associated with	amyloidosis
multiple myeloma	is associated with	peripheral neuropathy
multiple myeloma	is associated with	osteolytic lesions
multiple myeloma	is associated with	fractures
multiple myeloma	is associated with	fatigue
multiple myeloma	is associated with	weight loss
multiple myeloma	is associated with	constipation
multiple myeloma	is associated with	hyperuricemia
multiple myeloma	is associated with	thrombosis
multiple myeloma	is associated with	hypogammaglobulinemia
multiple myeloma	is associated with	immunoparesis
multiple myeloma	is associated with	increased mortality
multiple myeloma	is a risk factor for	cardiovascular disease
multiple myeloma	is a risk factor for	pulmonary embolism
multiple myeloma	is a risk factor for	sepsis
multiple myeloma	is a risk factor for	delirium
multiple myeloma	is a risk factor for	depression
multiple myeloma	is a risk factor for	malnutrition
multiple myeloma	is a risk factor for	falls
multiple myeloma	is a risk factor for	readmission
multiple myeloma	is a risk factor for	ICU admission
multiple myeloma	is a risk factor for	mortality
multiple myeloma	is a predictor of	progression
multiple myeloma	is a predictor of	relapse
multiple myeloma	is a predictor of	treatment response
multiple myeloma	is a predictor of	survival
multiple myeloma	is a predictor of	renal decline
multiple myeloma	is a predictor of	bone fracture
multiple myeloma	is a predictor of	infection rate
multiple myeloma	is a predictor of	neuropathy severity
multiple myeloma	is a predictor of	hypercalcemia risk
multiple myeloma	is a predictor of	hyperviscosity risk
multiple myeloma	is a predictor of	amyloidosis risk
multiple myeloma	is a predictor of	treatment toxicity
multiple myeloma	is a predictor of	quality of life
multiple myeloma	is a predictor of	hospitalization duration
multiple myeloma	is a predictor of	cost burden
multiple myeloma	is a predictor of	adherence
multiple myeloma	is a predictor of	drug resistance
multiple myeloma	is a predictor of	clonal evolution
multiple myeloma	is a predictor of	cytogenetic abnormality
multiple myeloma	is a predictor of	high‑risk cytogenetics
multiple myeloma	is a predictor of	del(17p)
multiple myeloma	is a predictor of	t(4;14)
multiple myeloma	is a predictor of	t(14;16)
multiple myeloma	is a predictor of	1q21 gain
multiple myeloma	is a predictor of	hyperdiploidy
multiple myeloma	is a predictor of	hypodiploidy
multiple myeloma	is a predictor of	extramedullary disease
multiple myeloma	is a predictor of	plasmacytoma
multiple myeloma	is a predictor of	plasmablastic transformation
multiple myeloma	is a predictor of	plasma cell leukemia
multiple myeloma	is a predictor of	overall survival
multiple myeloma	is a predictor of	progression‑free survival
multiple myeloma	is a predictor of	time to next treatment
multiple myeloma	is a predictor of	response depth
multiple myeloma	is a predictor of	minimal residual disease
multiple myeloma	is a predictor of	relapse risk
multiple myeloma	is a predictor of	drug‑specific toxicity
multiple myeloma	is a predictor of	infection severity
multiple myeloma	is a predictor of	anemia severity
multiple myeloma	is a predictor of	hypercalcemia severity
multiple myeloma	is a predictor of	renal impairment
multiple myeloma	is a predictor of	bone lesion burden
multiple myeloma	is a predictor of	quality‑adjusted life expectancy
multiple myeloma	is a predictor of	cost‑effectiveness of therapy
multiple myeloma	is a predictor of	hospital readmission
multiple myeloma	is a predictor of	ICU transfer
multiple myeloma	is a predictor of	mortality within 30 days
multiple myeloma	is a predictor of	mortality within 1 year
